WO2007127688A3 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 - Google Patents

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 Download PDF

Info

Publication number
WO2007127688A3
WO2007127688A3 PCT/US2007/067182 US2007067182W WO2007127688A3 WO 2007127688 A3 WO2007127688 A3 WO 2007127688A3 US 2007067182 W US2007067182 W US 2007067182W WO 2007127688 A3 WO2007127688 A3 WO 2007127688A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inhibitors
beta
hydroxysteroid dehydrogenase
formula
Prior art date
Application number
PCT/US2007/067182
Other languages
French (fr)
Other versions
WO2007127688A2 (en
Inventor
Julie Kay Bush
Marvin Martin Hansen
Renhua Li
Thomas Edward Mabry
Nancy June Snyder
Owen Brendan Wallace
Yanping Xu
Original Assignee
Lilly Co Eli
Julie Kay Bush
Marvin Martin Hansen
Renhua Li
Thomas Edward Mabry
Nancy June Snyder
Owen Brendan Wallace
Yanping Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007127688(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2007244955A priority Critical patent/AU2007244955B2/en
Priority to SI200730353T priority patent/SI2021336T1/en
Priority to CA2646624A priority patent/CA2646624C/en
Priority to DK07761091.3T priority patent/DK2021336T3/en
Priority to PL07761091T priority patent/PL2021336T3/en
Priority to CN2007800149090A priority patent/CN101432275B/en
Priority to BRPI0710467-7A priority patent/BRPI0710467A2/en
Priority to US12/297,873 priority patent/US8153807B2/en
Priority to EA200870470A priority patent/EA015106B1/en
Application filed by Lilly Co Eli, Julie Kay Bush, Marvin Martin Hansen, Renhua Li, Thomas Edward Mabry, Nancy June Snyder, Owen Brendan Wallace, Yanping Xu filed Critical Lilly Co Eli
Priority to EP07761091A priority patent/EP2021336B1/en
Priority to JP2009507912A priority patent/JP5269765B2/en
Priority to DE602007007473T priority patent/DE602007007473D1/en
Priority to KR1020087025921A priority patent/KR101059614B1/en
Priority to MX2008013649A priority patent/MX2008013649A/en
Priority to NZ571176A priority patent/NZ571176A/en
Priority to AT07761091T priority patent/ATE472542T1/en
Publication of WO2007127688A2 publication Critical patent/WO2007127688A2/en
Publication of WO2007127688A3 publication Critical patent/WO2007127688A3/en
Priority to NO20084318A priority patent/NO20084318L/en
Priority to TNP2008000417A priority patent/TNSN08417A1/en
Priority to IL194810A priority patent/IL194810A/en
Priority to HK09104719.3A priority patent/HK1126208A1/en
Priority to HR20100397T priority patent/HRP20100397T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention discloses novel compounds of Formula I: (I) having 11 -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 -HSD type 1 activity.
PCT/US2007/067182 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 WO2007127688A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
EP07761091A EP2021336B1 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP2009507912A JP5269765B2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-β-hydroxysteroid dehydrogenase 1
CA2646624A CA2646624C (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DK07761091.3T DK2021336T3 (en) 2006-04-24 2007-04-23 11-beta-hydroxysteroid dehydrogenase-1 inhibitors
PL07761091T PL2021336T3 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN2007800149090A CN101432275B (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710467-7A BRPI0710467A2 (en) 2006-04-24 2007-04-23 compound, pharmaceutical composition, use of a compound, and intermediate
US12/297,873 US8153807B2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA200870470A EA015106B1 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI200730353T SI2021336T1 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AT07761091T ATE472542T1 (en) 2006-04-24 2007-04-23 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 INHIBITORS
AU2007244955A AU2007244955B2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2008013649A MX2008013649A (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1.
KR1020087025921A KR101059614B1 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DE602007007473T DE602007007473D1 (en) 2006-04-24 2007-04-23 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
NZ571176A NZ571176A (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteriod dehydrogenase 1
NO20084318A NO20084318L (en) 2006-04-24 2008-10-15 Inhibitors of II-beta-hydroxysteroid dehydrogenase I
TNP2008000417A TNSN08417A1 (en) 2006-04-24 2008-10-20 Inhibitors of 11-beta- hydroxysteroid dehydrogenase 1
IL194810A IL194810A (en) 2006-04-24 2008-10-22 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
HK09104719.3A HK1126208A1 (en) 2006-04-24 2009-05-25 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
HR20100397T HRP20100397T1 (en) 2006-04-24 2010-07-20 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74547506P 2006-04-24 2006-04-24
US60/745,475 2006-04-24

Publications (2)

Publication Number Publication Date
WO2007127688A2 WO2007127688A2 (en) 2007-11-08
WO2007127688A3 true WO2007127688A3 (en) 2007-12-21

Family

ID=38564359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067182 WO2007127688A2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Country Status (33)

Country Link
US (1) US8153807B2 (en)
EP (1) EP2021336B1 (en)
JP (1) JP5269765B2 (en)
KR (1) KR101059614B1 (en)
CN (1) CN101432275B (en)
AT (1) ATE472542T1 (en)
AU (1) AU2007244955B2 (en)
BR (1) BRPI0710467A2 (en)
CA (1) CA2646624C (en)
CO (1) CO6140034A2 (en)
CR (2) CR10402A (en)
CY (1) CY1110753T1 (en)
DE (1) DE602007007473D1 (en)
DK (1) DK2021336T3 (en)
EA (1) EA015106B1 (en)
EC (1) ECSP088833A (en)
ES (1) ES2345792T3 (en)
HK (1) HK1126208A1 (en)
HR (1) HRP20100397T1 (en)
IL (1) IL194810A (en)
MA (1) MA30686B1 (en)
MX (1) MX2008013649A (en)
MY (1) MY148079A (en)
NO (1) NO20084318L (en)
NZ (1) NZ571176A (en)
PL (1) PL2021336T3 (en)
PT (1) PT2021336E (en)
RS (1) RS51450B (en)
SI (1) SI2021336T1 (en)
TN (1) TNSN08417A1 (en)
UA (1) UA94741C2 (en)
WO (1) WO2007127688A2 (en)
ZA (1) ZA200808687B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014718B1 (en) 2006-04-21 2011-02-28 Эли Лилли Энд Компани Biphenyl amidelactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2029579B1 (en) * 2006-04-21 2014-12-31 Eli Lilly And Company Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2646678C (en) 2006-04-21 2014-02-11 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710262A2 (en) 2006-04-24 2011-08-09 Lilly Co Eli compound, pharmaceutical composition, and intermediate
MX2008013658A (en) 2006-04-24 2008-11-04 Lilly Co Eli Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1.
US8148534B2 (en) 2006-04-25 2012-04-03 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101432265B (en) 2006-04-25 2011-12-14 伊莱利利公司 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ES2336849T3 (en) 2006-04-25 2010-04-16 Eli Lilly And Company INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE 1.
KR101060016B1 (en) 2006-04-28 2011-08-29 일라이 릴리 앤드 캄파니 Piperidinyl substituted pyrrolidinone as inhibitor of 11-beta-hydroxysteroid dehydrogenase 1
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
JP6969001B2 (en) * 2017-12-21 2021-11-24 広東衆生睿創生物科技有限公司Guangdong Raynovent Biotech Co., Ltd. Amorphous pyrrolidine derivative used as a PPAR agonist and its production method
CN110483514B (en) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 Cyano-substituted cyclic hydrazine derivative and application thereof
CN110724142B (en) * 2019-10-29 2022-09-02 启元生物(杭州)有限公司 Amide or sulfonamide substituted hydrazine derivatives as JAK kinase inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005108360A1 (en) * 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2005108361A1 (en) * 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006049952A1 (en) * 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006068992A1 (en) * 2004-12-20 2006-06-29 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006104280A1 (en) * 2005-03-31 2006-10-05 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for diabetes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515956A (en) 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 11.beta.-hydroxysteroid dehydrogenase type 1 active spiro compound
EP1812005B1 (en) 2004-11-10 2015-09-16 Incyte Corporation Lactam compounds and their use as pharmaceuticals
EP1830840B1 (en) 2004-12-21 2008-07-16 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007066921A1 (en) * 2005-12-08 2007-06-14 Ho Young Lee Structure of sticking extraneous matter and warm foot digital compression plate
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CA2646678C (en) 2006-04-21 2014-02-11 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA014718B1 (en) 2006-04-21 2011-02-28 Эли Лилли Энд Компани Biphenyl amidelactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2029579B1 (en) 2006-04-21 2014-12-31 Eli Lilly And Company Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0710262A2 (en) 2006-04-24 2011-08-09 Lilly Co Eli compound, pharmaceutical composition, and intermediate
MX2008013658A (en) 2006-04-24 2008-11-04 Lilly Co Eli Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1.
US8148534B2 (en) 2006-04-25 2012-04-03 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ES2336849T3 (en) 2006-04-25 2010-04-16 Eli Lilly And Company INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE 1.
CN101432265B (en) 2006-04-25 2011-12-14 伊莱利利公司 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
KR101060016B1 (en) 2006-04-28 2011-08-29 일라이 릴리 앤드 캄파니 Piperidinyl substituted pyrrolidinone as inhibitor of 11-beta-hydroxysteroid dehydrogenase 1
US20090008890A1 (en) * 2007-06-13 2009-01-08 Woodford James R Suspension system for an all-terrain vehicle
CL2008001839A1 (en) 2007-06-21 2009-01-16 Incyte Holdings Corp Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005108360A1 (en) * 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2005108361A1 (en) * 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006049952A1 (en) * 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006068992A1 (en) * 2004-12-20 2006-06-29 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006104280A1 (en) * 2005-03-31 2006-10-05 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YEH ET AL: "Discovery of orally active butyrolactam 11beta-HSD1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 16, no. 21, 1 November 2006 (2006-11-01), pages 5555 - 5560, XP005663491, ISSN: 0960-894X *

Also Published As

Publication number Publication date
EP2021336A2 (en) 2009-02-11
JP2009534468A (en) 2009-09-24
CY1110753T1 (en) 2015-06-10
IL194810A (en) 2012-12-31
CA2646624C (en) 2013-08-06
ECSP088833A (en) 2008-11-27
KR101059614B1 (en) 2011-08-25
WO2007127688A2 (en) 2007-11-08
EA200870470A1 (en) 2009-04-28
EP2021336B1 (en) 2010-06-30
HRP20100397T1 (en) 2010-09-30
EA015106B1 (en) 2011-06-30
CR10402A (en) 2009-07-13
HK1126208A1 (en) 2009-08-28
IL194810A0 (en) 2009-09-22
BRPI0710467A2 (en) 2011-08-16
CN101432275A (en) 2009-05-13
TNSN08417A1 (en) 2010-04-14
ZA200808687B (en) 2010-01-27
CA2646624A1 (en) 2007-11-08
DK2021336T3 (en) 2010-09-13
RS51450B (en) 2011-04-30
MY148079A (en) 2013-02-28
NO20084318L (en) 2008-10-15
AU2007244955B2 (en) 2011-12-08
CO6140034A2 (en) 2010-03-19
CN101432275B (en) 2013-10-30
ATE472542T1 (en) 2010-07-15
US20090111809A1 (en) 2009-04-30
ES2345792T3 (en) 2010-10-01
PT2021336E (en) 2010-07-19
MX2008013649A (en) 2008-11-04
AU2007244955A1 (en) 2007-11-08
DE602007007473D1 (en) 2010-08-12
SI2021336T1 (en) 2010-11-30
NZ571176A (en) 2011-10-28
JP5269765B2 (en) 2013-08-21
US8153807B2 (en) 2012-04-10
MA30686B1 (en) 2009-09-01
CR10401A (en) 2009-01-14
KR20090034797A (en) 2009-04-08
PL2021336T3 (en) 2010-11-30
UA94741C2 (en) 2011-06-10

Similar Documents

Publication Publication Date Title
WO2007127688A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127763A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007124254A3 (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TNSN08432A1 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2049475T3 (en) Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007124337A8 (en) Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
PL2029529T3 (en) Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI1807072T1 (en) Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761091

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 571176

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2646624

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007244955

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 8104/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 08110817

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008101727

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 12008502344

Country of ref document: PH

Ref document number: 12297873

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 194810

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2007244955

Country of ref document: AU

Date of ref document: 20070423

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013649

Country of ref document: MX

Ref document number: 2009507912

Country of ref document: JP

Ref document number: 1020087025921

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200780014909.0

Country of ref document: CN

Ref document number: CR2008-010401

Country of ref document: CR

Ref document number: CR2008-010402

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2008000638

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007761091

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200870470

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-2010/0399

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0710467

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081020